4.7 Article

Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging

Journal

EUROPEAN JOURNAL OF CANCER
Volume 182, Issue -, Pages 122-131

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.12.026

Keywords

Microsatellite instability; Colon cancer; Artificial intelligence; Deep learning; Infrared imaging; Label-free; Convolutional neural networks

Categories

Ask authors/readers for more resources

This study proposes a novel label-free digital pathology approach using infrared imaging and artificial intelligence to classify microsatellite instability (MSI) vs. microsatellite stability (MSS) in unstained tissue sections. The two-step convolutional neural networks (CNN) algorithm achieves high classification accuracy and rapidity in early colon cancer tissue samples.
Purpose: Microsatellite instability (MSI) due to mismatch repair (MMR) defects accounts for 15-20% of colon cancers (CC). MSI testing is currently standard of care in CC with immunohistochemistry of the four MMR proteins representing the gold standard. Instead, label-free quantum cascade laser (QCL) based infrared (IR) imaging combined with artificial intelligence (AI) may classify MSI/microsatellite stability (MSS) in unstained tissue sections user-independently and tissue preserving. Methods: Paraffin-embedded unstained tissue sections of early CC from patients participating in the multicentre AIO ColoPredict Plus (CPP) 2.0 registry were analysed after dividing into three groups (training, test, and validation). IR images of tissue sections using QCL-IR micro-scopes were classified by AI (convolutional neural networks [CNN]) using a two-step approach. The first CNN (modified U-Net) detected areas of cancer while the second CNN (VGG-Net) classified MSI/MSS. End-points were area under receiver operating characteristic (AUROC) and area under precision recall curve (AUPRC). Results: The cancer detection in the first step was based on 629 patients (train n = 273, test n = 138, and validation n = 218). Resulting classification AUROC was 1.0 for the validation dataset. The second step classifying MSI/MSS was performed on 547 patients (train n = 331, test n = 69, and validation n = 147) reaching AUROC and AUPRC of 0.9 and 0.74, respec-tively, for the validation cohort.Conclusion: Our novel label-free digital pathology approach accurately and rapidly classifies MSI vs. MSS. The tissue sections analysed were not processed leaving the sample unmodified for subsequent analyses. Our approach demonstrates an AI-based decision support tool poten-tially driving improved patient stratification and precision oncology in the future. 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available